mirtazapine and ketamine

mirtazapine has been researched along with ketamine in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (22.22)	29.6817
2010's	6 (66.67)	24.3611
2020's	1 (11.11)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Lombardo, F; Obach, RS; Waters, NJ	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
García-Fuster, MJ; García-Sevilla, JA	1
Berenato, F; Chan, YH; Grossman, SK; Korbutov, J; Lavery, MJ; Lee, HG; Valdes-Rodriguez, R; Yosipovitch, G	1
Bervoets, AC; Bouwmeester, NH; der Ark, PV; Fedgchin, M; Garssen, J; Mooren, L; Morrison, R; Singh, J; van Amerongen, G; van de Loo, AJAE; van Gerven, J; Verster, JC; Wajs, E; Zuiker, R	1
Azevedo, A; Ferreira, S; Sanches, M; Selores, M; Velho, GC	1

Reviews

1 review(s) available for mirtazapine and ketamine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for mirtazapine and ketamine

Article	Year
The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study. Psychopharmacology, 2017, Volume: 234, Issue:21 Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Attention; Automobile Driving; Cross-Over Studies; Double-Blind Method; Female; Humans; Ketamine; Male; Mianserin; Middle Aged; Mirtazapine; Orientation, Spatial; Psychomotor Performance; Young Adult	2017

Article

Year

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.

Psychopharmacology, 2017, Volume: 234, Issue:21

Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Attention; Automobile Driving; Cross-Over Studies; Double-Blind Method; Female; Humans; Ketamine; Male; Mianserin; Middle Aged; Mirtazapine; Orientation, Spatial; Psychomotor Performance; Young Adult

2017

Other Studies

7 other study(ies) available for mirtazapine and ketamine

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration. Psychopharmacology, 2016, Volume: 233, Issue:15-16 Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Apoptosis; Autoreceptors; Blotting, Western; Brain; CASP8 and FADD-Like Apoptosis Regulating Protein; Cerebral Cortex; Clorgyline; Desipramine; Electroshock; Excitatory Amino Acid Antagonists; Fas-Associated Death Domain Protein; Fluoxetine; Idazoxan; Indans; Ketamine; Male; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Phenelzine; Phosphoproteins; Phosphorylation; Rats; RNA-Binding Proteins; Thiazoles	2016
Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability. Journal of the American Academy of Dermatology, 2017, Volume: 76, Issue:4 Topics: Aged; Amines; Amitriptyline; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Ketamine; Lidocaine; Male; Mianserin; Mirtazapine; Pain Measurement; Pruritus; Retrospective Studies	2017
Epidermolysis Bullosa Pruriginosa successfully treated with concomitant topical and systemic agents. The Australasian journal of dermatology, 2020, Volume: 61, Issue:4 Topics: Administration, Topical; Amitriptyline; Analgesics; Drug Therapy, Combination; Epidermolysis Bullosa Dystrophica; Histamine H1 Antagonists; Humans; Ketamine; Male; Middle Aged; Mirtazapine; Pruritus	2020